We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Linde
LIN
$221B
| $1.31M | 0.15% |
+3,522
| New | +$1.34M |
|
177
Axcelis
ACLS
$4.01B
| $1.31M | 0.15% |
+8,013
| New | +$1.41M |
|
|
VRN
178
DELISTED
Veren
VRN
| $1.3M | 0.15% |
+157,046
| New | +$1.25M |
|
179
Trex
TREX
$4.51B
| $1.29M | 0.15% |
21,006
+17,794
| +554% | +$1.22M |
|
180
Shopify
SHOP
$152B
| $1.29M | 0.15% |
+23,609
| New | +$1.43M |
|
181
UiPath
PATH
$6.61B
| $1.28M | 0.15% |
75,101
-24,394
| -25% | -$406K |
|
182
Paycom
PAYC
$7.64B
| $1.28M | 0.15% |
4,935
+3,458
| +234% | +$1.05M |
|
183
ITT
ITT
$17.5B
| $1.28M | 0.15% |
+13,029
| New | +$1.28M |
|
184
Dick's Sporting Goods
DKS
$17.5B
| $1.27M | 0.15% |
+11,680
| New | +$1.48M |
|
185
Manhattan Associates
MANH
$11.2B
| $1.27M | 0.15% |
6,408
+3,347
| +109% | +$653K |
|
|
ERF
186
DELISTED
Enerplus Corporation
ERF
| $1.26M | 0.15% |
71,522
+60,899
| +573% | +$1.01M |
|
187
Jackson Financial
JXN
$8.53B
| $1.26M | 0.15% |
+32,955
| New | +$1.15M |
|
188
MasTec
MTZ
$21.1B
| $1.26M | 0.15% |
+17,499
| New | +$1.74M |
|
189
Agilent Technologies
A
$39.1B
| $1.25M | 0.15% |
+11,239
| New | +$1.35M |
|
190
Hormel Foods
HRL
$13.8B
| $1.25M | 0.15% |
+32,835
| New | +$1.29M |
|
191
ON Semiconductor
ON
$31.8B
| $1.24M | 0.15% |
13,374
-4,649
| -26% | -$452K |
|
192
Tecnoglass Holdings Inc.
TGLS
$1.93B
| $1.24M | 0.15% |
37,663
+25,420
| +208% | +$1.04M |
|
193
Navient
NAVI
$789M
| $1.24M | 0.15% |
72,037
+24,516
| +52% | +$441K |
|
194
Commercial Metals
CMC
$7.6B
| $1.23M | 0.14% |
24,794
-4,549
| -16% | -$247K |
|
195
Revolution Medicines
RVMD
$39.9B
| $1.22M | 0.14% |
44,247
+34,944
| +376% | +$1.04M |
|
196
Logitech
LOGI
$14.7B
| $1.22M | 0.14% |
+17,745
| New | +$1.2M |
|
197
TechnipFMC
FTI
$28.1B
| $1.22M | 0.14% |
60,061
+40,838
| +212% | +$771K |
|
198
Federated Hermes
FHI
$4.55B
| $1.22M | 0.14% |
+35,892
| New | +$1.24M |
|
199
Estee Lauder
EL
$30.4B
| $1.21M | 0.14% |
8,349
-1,237
| -13% | -$206K |
|
200
Ameriprise Financial
AMP
$48.3B
| $1.2M | 0.14% |
3,641
+903
| +33% | +$308K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.